ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Indocyanine GreenSkull Base Neoplasms
Interventions
PROCEDURE

Indocyanine Green

"Tumor resection, direct visualization of the chiasm and both optic nerves and ICG administration will be provided as it is recommended by the standard of care. ICG will be administered by an injection of 5 mg of ICG diluted in a 10 mL syringe performed in the line closest to the heart followed by a 10-mL saline bolus. Using near-infrared lighting, the investigators will determine the time between anterior cerebral arteries (ACA) peak luminescence to the peak luminescence of the superior hypophyseal arteries enveloping the optic chiasm (ACA to chiasm time). Because luminescence of large vessels precedes small arterial penetration, signal from the ACAs was considered as time 0 to account for possible differences in the arm-brain time between patients. In addition, the investigators will analyze the proportion of superior hypophyseal branches on the chiasm that luminesced from ICG."

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT06501716 - ICG Angiogram as a Predictor of Postoperative Visual Function After EEA Surgery | Biotech Hunter | Biotech Hunter